XERMELO™ further reduces carcinoid syndrome diarrhea
About the Study
In a clinical study, patients with carcinoid syndrome diarrhea received XERMELO™ in addition to SSA injections. They were followed for 12 weeks, and observed for reductions in daily bowel movements.
Remember to talk to your doctor to see if XERMELO™ may be right for you.
See how XERMELO™ can fit into your everyday schedule